Abstract
Asthma has a high prevalence worldwide with a high incidence in primary care settings in many countries. It is by definition a variable disease with a broad spectrum of clinical phenotypes, in which management and treatment can be difficult. The aim of asthma treatment is optimal control of the disease, which according to Global Initiative for Asthma (GINA) guidelines implies both symptom control and prevention of exacerbations. Despite several treatment options, studies show that about half of the patients have poor asthma control. When asthma is not controlled, it decreases the quality of life, increases the risk of exacerbations and premature death and is a high cost for the society.
Original language | English |
---|---|
Article number | 16016 |
Pages (from-to) | 1-3 |
Number of pages | 3 |
Journal | npj Primary Care Respiratory Medicine |
Volume | 26 |
Early online date | 14 Apr 2016 |
DOIs | |
Publication status | Published - 2016 |
Bibliographical note
FundingThe IPCRG provided funding for this research project as an UNLOCK Group study for which the funding was obtained through an unrestricted grant by Novartis AG, Basel, Switzerland. Novartis has no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. This study will include data from the Optimum Patient Care Research Database and is undertaken in collaboration with Optimum Patient Care and the Respiratory Effectiveness Group.